Awesome results! New Gold Standard Coming IMHO 94-100% CR potential. Out of 11 PH2 patients with evaluable data at 90 days, 8 are CR, 2 are PR ( have potential to become CR if cancer is from UTUC) and 1 is NR ( patient who passed away but had a negative cytology at 30 days which is 95% indicative of CR status at that time point). If we add 2 optimized treated patients from PH1 we get
10 out of 13 CR, 2 PR , and one NR. 7 patients still pending data have not yet reached 90 days time point.. Good that they treated 6 more anther 5-10 for Accelerated FDA approval IMO if they keep this up.. So for the 5 newly evaluable patients, 4 were CR and 1 was PR which are added to the 6 from last Quarterly for a total of 11 PH2 patients.